Kazia Therapeutics (KZIA) Receivables - Accured (2016)

Kazia Therapeutics' (KZIA) quarterly Receivables - Accured came in at -$750.16 in Q4 2016, little changed on a QoQ basis from -$746.7 in Q2 2016.

Kazia Therapeutics (KZIA) Receivables - Accured (2016) Analysis & Trends

Kazia Therapeutics (KZIA) has 1 years of Receivables - Accured data on file, last reported at -$750.16 in Q4 2016.

Quarterly Receivables - Accured changed N/A year-over-year to -$750.16 in Q4 2016, while the trailing twelve-month figure through Dec 2016 was -$750.16 (changed N/A YoY) and the FY2016 annual result came in at -$750.16, changed N/A from the prior year.
Receivables - Accured held at -$750.16 in Q4 2016, from -$746.7 in the prior quarter.
In the past five years, Receivables - Accured ranged from a high of -$746.7 in Q2 2016 to a low of -$750.16 in Q4 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acc. Int. Receivables (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Kazia Therapeutics	4.22 Bn	4.22 Bn	-	-

Download Data